Early histological changes in the kidney of people with morbid obesity

Nephrology Dialysis Transplantation

Volumn 24, Issue 12, 2009, Pages 3732-3738

  Goumenos, Dimitrios S ^a   Kawar, Bisher ^b   El Nahas, Meguid ^b   Conti, Sara ^c   Wagner, Bart ^b   Spyropoulos, Charalambos ^a   Vlachojannis, John G ^a   Benigni, Ariela ^c   Kalfarentzos, Fotios ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Glomerular disease; Glomerular volume; Obesity; Podocytes

Indexed keywords

CHOLESTEROL; HEMOGLOBIN A1C; TRIACYLGLYCEROL;

ADULT; ARTICLE; BILIOPANCREATIC BYPASS; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; FEMALE; GLOMERULUS BASEMENT MEMBRANE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY INJURY; KIDNEY PARENCHYMA; MALE; MESANGIUM; MORBID OBESITY; PODOCYTE; PRIORITY JOURNAL; ROUX Y ANASTOMOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; FEMALE; HUMANS; KIDNEY; MALE; OBESITY, MORBID; TIME FACTORS;

EID: 71049171278     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp329     Document Type: Article

References (34)

1. Adelman RD. Obesity and renal disease. Curr Opin Nephrol Hyper-tens 2002; 11: 331-335
2. Flegal KM, Carrol MD, Ogden CL et al. Prevalence and trends in obesity among US adults. JAMA 2002; 288: 1723-1727
3. Cignarelli M, Lamacchia O. Obesity and kidney disease. Nutr Metab Cardiovasc Dis 2007; 17: 757-762
4. Ogden CL, Carroll MD, Curtin LR et al. Prevalence of overweight and obesityin the United States, 1999-2004. JAMA 2006; 295: 1549-1555
5. Abrass CK. Overview: Obesity: What does it have to do with kidney disease? J Am Soc Nephrol 2004; 15: 2768-2772
6. Kramer H and Luke A. Obesity and kidney disease: a big dilemma. Curr Opin Nephrol Hypertens 2007; 16: 237-241
7. Wang Y, Chen X, Song Y et al. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int 2008; 73: 19-33 (Pubitemid 350273639)
8. Praga M, Morales E. Obesity and progression of renal failure. Curr Opin Nephrol Hypertens 2006; 15: 481-486
9. Bagby S. Obesity-initiated metabolic syndrome and the kidney: A recipe for chronic kidney disease? J Am Soc Nephrol 2004; 15: 2775-2791
10. Kambham N, Markowwitz GS, Valeri AM et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498-1509
11. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection in Adults (Adult Treatment Panel III). Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA 2001; 285: 2486-2497
12. KalfarentzosF, PapadoulasS, SkroubisG et al. Prospective evaluation of biliopancreatic diversion with Roux-en-Y gastric bypass in the super obese. J Gastrointest Surg 2004; 8: 479-488
13. Rea DJ, Heimbach JK, Grande JP et al. Glomerular volume and renal histology in obese and non-obese living kidney donors. Kidney Int 2006; 70: 1636-1641
14. Ruggenenti P, Cravedi P, Sghirlanzoni MC et al. Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin J Am Soc Nephrol 2008; 3: 1652-1659
15. Praga M, Hernandez E, Morales E et al. Clinical features and long-term outcome of obesity-associated focal segmental glomeruloscle-rosis. Nephrol Dial Transplant 2001; 16: 1790-1798
16. Chen HM, Li SJ, Chen HP et al. Obesity-related glomerulopathy in China: a case series of 90 patients. Am J Kidney Dis 2008; 52: 58-65
17. Serra A, Romero R, Lopez D et al. Renal injury in the extremely obese patients with renal function. Kidney Int 2008; 73: 947-955
18. Chen HM, Liu ZH, Zeng CH et al. Podocyte lesions in patients with obesity-related glomerulopathy. Am J Kidney Dis 2006; 48: 772-779
19. Pollock CA, Poronnik P. Albumin transport and processing by the proximal tubule: physiology and pathophysiology. Curr Opin Nephrol Hypertens 2007; 16: 359-364
20. The Diabetes Control and Complications Trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
21. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
22. Bangstad HJ, Osterby R, Rudgerg S et al. Kidney function and glomerulopathy over 8 years in young patients with type I (insulin-dependent) diabetes mellitus and microalbuminuria. Diabetologia 2002; 45: 253-261
23. Bangstad HJ, Osterby R, Dahl-Jorgensen K et al. Improvement of blood glucose control in IDDM patients retards progression of morphological changes in early diabetic nephropathy. Diabetologia 1994; 37: 483-490
24. Wirta O, Oasternack A, Laippala P et al. Glomerular filtration rate and kidney size after six years disease duration in non-insulin-dependent diabetic subjects. Clin Nephrol 1996; 45: 10-17
25. Maddox DA, Alavi FK, Santella RN et al. Prevention of obesity-linked renal disease: age-dependent effects of dietary food restriction. Kidney Int 2002; 62: 208-219
26. Courbebaisse M,Thervet E, Souberbielle JCet al. Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Kidney Int 2008; 75: 646-651
27. Ilahi M, Armas LA, Heaney RP. Pharmacokinetics of a single, large dose of cholecalciferol. Am J Clin Nutr 2008; 87: 688-691
28. Khaw KT, Scragg R, Murphy S. Single-dose cholecalciferol suppresses the winter increase in parathyroid hormone concentrations in healthy older men and women: a randomized trial. Am J Clin Nutr 1994; 59: 1040-1044
29. Halloran BP, Schaefer P, Lifschitz M et al. Plasma vitamin D metabolite concentrations in chronic renal failure: effect of oral administration of 25-hydroxyvitamin D3. J Clin Endocrinol Metab 1984; 59: 1063-1069
30. Slatopolsky E, Weerts C, Thielan J et al. Marked suppression of secondary hyperparathyroidismbyintravenous administrationof1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-2143
31. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456 (Pubitemid 36910023)
32. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187
33. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodial-ysis patients. Kidney Int 2006; 70: 771-780
34. Chel V, Wijnhoven HA, Smit JH et al. Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents. Osteoporos Int 2008; 19: 663-671